PRVA Earnings Prediction
The chart below shows how PRVA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, PRVA sees a -0.05% change in stock price 10 days leading up to the earnings, and a -0.37% change 10 days following the report. On the earnings day itself, the stock moves by +4.90%. This data can give you a slight idea of what to expect for the next quarter's release.
PRVA Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
460.90M
4.55%
5.25%
Gross Margin
10.01%
18.46%
0.60%
Operating Margin
1.69%
94.25%
10.46%
Net Margin
1.16%
118.87%
27.47%
EPS
0.03
50.00%
0.00%
No Data Available
PRVA Earnings Analysis
Privia Health Group Inc Corporation (PRVA.O) Earnings Conference Call
Positive
Strong Operational Performance: Privia Health exceeded the high end of all guidance metrics for 2024, showcasing strong operational execution and growth.
Provider Growth Impact: Implemented providers increased by 11.2% year-over-year, contributing to a 13.6% growth in fee-for-service collections.
EBITDA Growth and Efficiency: Adjusted EBITDA rose by 25.2%, with a margin expansion of 230 basis points year-over-year, indicating improved operational efficiency.
Record Free Cash Flow: The company generated a record $109.3 million in free cash flow in 2024, converting 121% of adjusted EBITDA, which strengthens its financial position.
Strong Cash Position: Privia ended the year with $491 million in cash and no debt, providing significant financial flexibility for future opportunities.
Market Presence in Care Programs: The company serves over 1.26 million attributed lives across various value-based care programs, reflecting its strong market presence.
Attributed Lives Growth: Total attributed lives increased by more than 11% year-over-year, driven by new provider growth and value-based care contracts.
Provider Retention Rate: Privia's gross provider retention rate of 98% highlights the satisfaction and loyalty of its providers to the platform.
Patient Satisfaction Score: The company's Net Promoter Score of 87 indicates a high level of patient satisfaction with the care provided by its medical groups.
Consistent Growth and Profitability: Privia has consistently delivered growth and profitability across various economic and regulatory cycles over the past seven years, demonstrating the resilience of its business model.
Negative
Medicare Advantage Challenges: Privia Health expects headwinds in Medicare Advantage over the next few years due to elevated utilization trends and changes in Star Scores.
Shared Savings Outlook: The company anticipates minimal increase in shared savings accruals year-over-year, reflecting ongoing challenges in the Medicare Advantage environment.
Collections Growth Analysis: Despite strong overall performance, practice collections growth was only 4.7% year-over-year in Q4 2024, which is lower than expected given the company's previous growth rates.
Cautious Growth Outlook: The initial guidance for 2025 assumes no new business development activity or capital deployment, indicating a cautious approach to growth in the near term.
Net Operating Loss Impact: The company is nearing the end of its net operating loss carryforward, which will lead to increased cash tax payments in 2025, impacting cash flow.
EBITDA Growth Reliance: While adjusted EBITDA is expected to grow, the guidance reflects a significant reliance on existing market performance rather than new growth initiatives.
PRVA FAQs
How does PRVA typically perform around its earnings report dates?
Is Privia Health Group Inc (PRVA) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
PRVA Earning Call Sentiment
Privia Health Group, Inc. (PRVA) Q4 2024 Earnings Call Transcript
PRVA.O
1.11%Positive
The earnings call highlights strong financial metrics, including a 25.2% increase in adjusted EBITDA and a 12.4% rise in margins, with a robust cash position and no debt. Despite some vague responses in the Q&A, the raised guidance for 2024 and strategic market expansion are positive indicators. The small-cap nature of the company suggests a more pronounced market reaction, likely resulting in a stock price increase of 2% to 8%.
